276,500 Shares in AngioDynamics, Inc. $ANGO Bought by Manatuck Hill Partners LLC

Key Points

• Manatuck Hill Partners bought 276,500 AngioDynamics shares worth approximately $3.6 million, representing about 0.67% of the company. Institutional investors collectively own 89.43% of the stock.
• AngioDynamics shares rose 1.1% to $15.95, near their 12-month high of $16.29. The company exceeded quarterly revenue and adjusted EPS expectations, although it remains unprofitable.
• Analyst sentiment is mixed: the stock has an average “Hold” rating and a $19.50 price target, with some firms issuing buy ratings while others downgraded it to “Sell” or “Strong Sell.”

Manatuck Hill Partners LLC bought a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 276,500 shares of the medical instruments supplier's stock, valued at approximately $3,597,000. AngioDynamics comprises 1.2% of Manatuck Hill Partners LLC's holdings, making the stock its 28th biggest position. Manatuck Hill Partners LLC owned about 0.67% of AngioDynamics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in shares of AngioDynamics during the 2nd quarter worth about $45,000. The Manufacturers Life Insurance Company bought a new position in shares of AngioDynamics in the 2nd quarter valued at approximately $132,000. Paradigm Capital Management Inc. NY bought a new position in shares of AngioDynamics in the 2nd quarter valued at approximately $8,732,000. Sanctuary Advisors LLC acquired a new stake in AngioDynamics in the 2nd quarter worth approximately $184,000. Finally, Weber Capital Management LLC ADV bought a new stake in AngioDynamics during the second quarter worth approximately $17,649,392,000. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Stock Up 1.1%

Shares of NASDAQ ANGO opened at $15.95 on Wednesday. The business's 50 day moving average is $14.11 and its two-hundred day moving average is $12.14. The company has a market cap of $659.21 million, a P/E ratio of -18.33 and a beta of 0.33. AngioDynamics, Inc. has a 12 month low of $9.39 and a 12 month high of $16.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to analysts' expectations of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Sell-side analysts expect that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company's stock, valued at $953,046.40. This represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on ANGO shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of AngioDynamics in a report on Friday, July 17th. Canaccord Genuity Group upped their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday. Zacks Research downgraded shares of AngioDynamics from a "hold" rating to a "strong sell" rating in a report on Thursday, July 16th. Finally, HC Wainwright boosted their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat, AngioDynamics currently has an average rating of "Hold" and an average price target of $19.50.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source